CureVac Withdraws First-Generation COVID-19 Vaccine Candidate to Focus on Alliance with GSK for Second-Generation mRNA Vaccines

CureVac Withdraws First-Generation COVID-19 Vaccine Candidate to Focus on Alliance with GSK for Second-Generation mRNA Vaccines

CureVac announced the strategic decision to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review with the European Medicines Agency (EMA) to focus on the development of second-generation mRNA vaccine candidates in collaboration with GlaxoSmithKline (GSK). Following recent communication with the EMA, the earliest potential approval of CVnCoV would come in the second quarter of 2022, by which time the candidates from the second-generation vaccine program will likely have progressed to late-stage clinical development. The decision is also aligned with the evolving dynamics of the pandemic response towards a greater need for differentiated vaccines to address the developing endemic SARS-CoV2 situation. 

“The global fight against COVID-19 continues, and we remain committed to making a difference with a safe and efficacious vaccine. This goal has not changed, but the requirements to effectively address the virus and emerging variants have changed. In the ongoing transition from acute pandemic to endemic, our decision to withdraw CVnCoV from the regulatory approval process and focus our efforts on second-generation mRNA vaccine candidates reflects e...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee